MacroGenics Reports $20.8M Revenue in Q1 2026, Driven by Contract Manufacturing and Royalty Increases

MacroGenics, Inc. reported a total revenue of $20.8 million for the first quarter of 2026, marking a 57.5% increase from $13.2 million in the same period of 2025. The revenue growth was primarily driven by a significant rise in contract manufacturing revenue, which increased to $14.0 million from $6.2 million, attributed to higher production volumes. Additionally, royalty revenue surged to $6.2 million, up from $0.4 million, reflecting increased sales of the FDA-approved product ZYNYZ. However, revenue from collaborative and other agreements fell sharply by 91% to $0.6 million, down from $6.6 million, indicating variability in milestone achievements from partners.

The company reported a net loss of $36.8 million for the quarter, a slight improvement compared to a net loss of $41.0 million in the prior year. This reduction in loss was supported by a decrease in total costs and expenses, which fell to $54.2 million from $55.8 million. Research and development expenses decreased to $35.0 million from $39.7 million, primarily due to reduced costs associated with discontinued projects. General and administrative expenses also saw a decline, totaling $9.7 million compared to $10.7 million in the previous year.

In terms of strategic developments, MacroGenics is in the process of selling its contract development and manufacturing operations (CDMO) to Bora Pharmaceuticals for $122.5 million, with the transaction expected to close in the third quarter of 2026. This sale is part of a strategic shift to focus on its core business of developing antibody-based therapeutics. The company anticipates that the proceeds from this sale, along with a recent $60 million payment from Sagard Healthcare Partners related to a royalty monetization agreement, will enhance its liquidity and support ongoing product development efforts.

As of March 31, 2026, MacroGenics had cash and cash equivalents of $66.5 million, an increase from $57.2 million at the end of 2025. The company also reported total assets of $217.9 million, down from $256.8 million at the end of the previous fiscal year, primarily due to a decrease in marketable securities. The company’s total liabilities increased to $196.7 million from $201.3 million, largely due to a rise in deferred revenue related to the royalty agreement.

Looking ahead, MacroGenics remains focused on advancing its clinical pipeline, which includes three proprietary product candidates currently in development. The company expects to continue incurring significant research and development expenses as it progresses through clinical trials. Management believes that the combination of current cash reserves, anticipated proceeds from the sale of the CDMO operations, and ongoing collaborations will provide sufficient liquidity to fund operations through at least 2028. However, the company acknowledges the inherent uncertainties in the biotechnology sector and the potential impact of macroeconomic conditions on its business operations.